Medicinal Cannabis

Susan Murray Excerpts

Thursday 30th January 2025 Westminster Hall

[Susan Murray (Mid Dunbartonshire) (LD)]

It is a pleasure to serve under your chairmanship, Ms McVey. It is undeniable that the United Kingdom’s relationship with cannabis remains fundamentally flawed. For too long, our prohibitionist stance has shaped public perception, linking cannabis with criminality instead of recognising its significant therapeutic value. Sometimes those who do recognise its therapeutic value are pushed into criminality. In reality, for many people across the UK, access to cannabis-based medicines can represent the difference between enduring chronic pain or multiple fits and leading a fulfilling life. That discrepancy is central to this debate.

Although, in principle, current regulations permit cannabis prescriptions for severe epilepsy, chemotherapy-induced nausea, muscle stiffness or spasms related to multiple sclerosis, genuine accessibility remains elusive. As the hon. Member for Strangford (Jim Shannon) has already mentioned, between 2018 and 2022 fewer than five NHS prescriptions for unlicensed medical cannabis, with the resulting funding issues, were issued, while private providers supplied nearly 90,000.

The stark contrast highlights the vast gulf between existing policy intentions and the lived experiences of patients seeking relief. Not only is this situation profoundly unjust for individuals who rely on cannabis to manage debilitating symptoms and have found no alternative, but it also entrenches an inherently two-tier healthcare system. Those with the financial means to travel for specialised appointments and cover private clinical expenses can access treatments that are virtually unobtainable for those who depend entirely on the NHS. While opinions on medical cannabis differ, I am sure we all agree that no one in Britain should be forced to pay exorbitant fees simply to secure a legally sanctioned and potentially life-changing medication.

The situation is further compounded by the fact that our outdated perspective on cannabis continues to hold back domestic medical innovation and economic growth. At a time when the Government project a modern vision for the nation, Britain lags behind international counterparts who have embraced a more progressive approach to cannabis-based treatments. By clinging to outdated stigmas, we not only fail our patients but also forgo opportunities to develop a robust medical cannabis sector, stifling both financial potential and essential healthcare advantages.

In the light of those realities, we must adopt a more compassionate and patient-centred strategy that does not penalise individuals for their economic circumstances. It is with this in mind that we must launch an investigation into the feasibility of GP prescribing of cannabis-based products, so that crucial treatments reach those who need them quickly. Such measures would reduce reliance on expensive private options, remove inequality and the push towards criminality, and alleviate unnecessary suffering of thousands of people nationwide.

Given the clear shortcomings of the current system, my colleagues in the Liberal Democrats and I urge the Government to reform policy in practice around medicinal cannabis across the UK. By doing so, we can ensure that patients receive the care they deserve while fostering a modern healthcare environment that truly reflects Britain’s commitment to innovation, compassion and equity.